TB-500, Thymosin Beta-4, TBI, and Stroke: Evidence Review

Research on full-length thymosin beta-4 (Tβ4) has reported neurological and tissue changes in rat models of traumatic brain injury (TBI) and embolic stroke. Those findings are preclinical. They do not establish TB-500 or thymosin beta-4 as a treatment for TBI, concussion, stroke, or post-stroke disability in people.

Suspected stroke or a dangerous head injury is an emergency. Do not delay emergency evaluation to obtain or use an experimental peptide. CDC advises calling 911 immediately for possible stroke and seeking emergency care for TBI danger signs such as worsening headache, repeated vomiting, seizure, weakness, slurred speech, increasing confusion, unequal pupils, or inability to wake.

Evidence summary

TB-500 is not full-length thymosin beta-4

Thymosin beta-4 is a naturally occurring 43-amino-acid peptide involved in actin binding and studied in cell migration, wound repair, inflammation, angiogenesis, and other processes. TB-500 is a synthetic N-acetylated fragment containing seven amino acids from positions 17–23 of thymosin beta-4.

That structural relationship does not make the two materials interchangeable. A fragment can differ from its parent peptide in receptor or protein interactions, distribution, stability, metabolism, aggregation, and immunogenicity. Evidence obtained with full-length thymosin beta-4 cannot be relabeled as TB-500 evidence without a direct bridging experiment.

This distinction matters because the central TBI and stroke papers discussed online used full-length thymosin beta-4. They did not test a vendor product labeled TB-500.

Traumatic-brain-injury evidence

Controlled cortical impact in rats

The principal TBI experiment used young adult male Wistar rats with a controlled cortical impact. The study included a sham group and injured animals assigned to saline or delayed full-length thymosin beta-4 treatment. Investigators measured sensorimotor performance, spatial learning, tissue loss, angiogenesis, neurogenesis, and oligodendrogenesis through 35 days.

Compared with saline, the thymosin beta-4 group showed improvements in selected behavioral and histological measurements. Lesion volume did not significantly change. The experiment was small, used one sex and species, and evaluated a standardized laboratory injury rather than the heterogeneous injuries, comorbidities, medications, and rehabilitation settings seen in patients.

The study supports a hypothesis about full-length thymosin beta-4 in a rat model. It does not establish that the effect would reproduce in humans, that it improves survival or patient-important disability, or that TB-500 has the same effect.

Mechanistic studies and reviews

Related cell and animal work has examined oligodendrocyte differentiation, myelination, angiogenesis, inflammatory signaling, and microRNA pathways. These endpoints may help explain a laboratory signal, but they are not substitutes for functional outcomes in a controlled human trial.

Several review articles describe thymosin beta-4 as a “candidate” neurorestorative agent. That language describes a research direction—not an approved treatment or a demonstrated clinical benefit.

Stroke evidence

Young-adult rat models

In a small embolic-stroke study in young male rats, full-length thymosin beta-4 was associated with improved neurological test scores and tissue-remodeling markers, while lesion volume did not significantly differ from control. A later dose-response experiment in the same general model reported functional differences at some exposures but not the highest exposure tested.

These experiments show that the response was not simply “more compound, more benefit.” They also came from a closely connected research program, making independent replication and broader model testing important before clinical translation.

Aged-rat model

An aged-rat embolic-stroke study produced a more mixed result. Thymosin beta-4 reduced infarct volume, but it did not significantly improve functional outcome, myelination, or gliosis compared with control. Both study groups also experienced deaths.

The aged-animal result is especially relevant to translation because stroke disproportionately affects older people. It illustrates why a tissue measurement or a result in young animals should not be presented as proof of rehabilitation benefit in patients.

What human evidence does—and does not—show

Full-length thymosin beta-4 has entered human research for non-neurological uses, including corneal, dermal, and cardiac investigations. Those studies cannot establish safety or efficacy for an injured brain, a different formulation, a different route, or the TB-500 fragment.

No published controlled human study identified for this review established that full-length thymosin beta-4 or TB-500:

• improves neurological function after TBI or concussion;
• reduces disability, recurrence, or mortality after stroke;
• improves post-stroke speech, mobility, cognition, or independence;
• reduces brain swelling or lesion size in patients;
• is safe alongside thrombolysis, thrombectomy, anticoagulation, antiseizure treatment, surgery, or rehabilitation; or
• has a clinically validated administration route, timing window, dose, or treatment duration for neurological injury.

Animal exposure schedules are experimental details, not human protocols. Converting them by body weight or publishing a “cycle” would be scientifically unsupported and potentially dangerous.

FDA status and safety

Neither TB-500 nor thymosin beta-4 is FDA-approved for TBI, stroke, concussion, or post-stroke recovery.

FDA’s 2026 review defines TB-500 as the N-acetylated LKKTETQ fragment and notes formulation, aggregation, degradation, peptide-impurity, and characterization concerns. FDA reported that it had not identified human exposure data for drug products containing the TB-500 fragment and lacked important information needed to determine whether it could cause harm when administered to humans.

At the July 2026 Pharmacy Compounding Advisory Committee meeting, the nominated use FDA evaluated for TB-500-related bulk substances was wound healing—not neurological injury. A nomination or committee discussion is not approval. FDA also states generally that compounded drugs are not FDA-approved and are not reviewed by the agency for safety, effectiveness, or quality before marketing.

A 2026 FDA warning letter separately described products labeled thymosin beta-4 as unapproved new drugs and biological products. “Research use only,” a pharmacy label, or a vendor certificate does not convert either substance into an approved neurological therapy.

Research-quality checklist

For laboratory or analytical research, verify:

1. whether the material is full-length thymosin beta-4 or the seven-amino-acid TB-500 fragment;
2. the complete sequence, N-terminal acetylation, C-terminal state, and salt or counterion form;
3. identity evidence, such as mass spectrometry, separately from chromatographic purity;
4. net peptide content, related peptides, aggregation, residual solvents, water, and counterions;
5. whether the cited experiment used the same molecule, formulation, species, injury model, and outcome;
6. neurological function separately from histology, infarct volume, or pathway markers; and
7. whether findings have been independently replicated outside the originating research group.

The TB-500 profile and general TB-500 evidence guide cover identity and non-neurological research in more detail. The peptide purity-testing guide explains analytical terminology. The source directory organizes public documentation signals, while the sourcing policy explains why inclusion is not an endorsement for human use. Use the research methodology to interpret evidence grades.

References

1. Xiong Y, et al. Treatment of traumatic brain injury with thymosin beta-4 in rats. Journal of Neurosurgery. 2011.
2. Xiong Y, et al. Neuroprotective and neurorestorative effects of thymosin beta-4 following experimental traumatic brain injury. Annals of the New York Academy of Sciences. 2012.
3. Morris DC, et al. Thymosin beta-4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010.
4. Morris DC, et al. A dose-response study of thymosin beta-4 for the treatment of acute stroke. Journal of the Neurological Sciences. 2014.
5. Morris DC, et al. Thymosin beta-4 for the treatment of acute stroke in aged rats. Neuroscience Letters. 2017.
6. US Food and Drug Administration. TB-500-related bulk drug substances: safety and effectiveness review. 2026.
7. US Food and Drug Administration. July 2026 Pharmacy Compounding Advisory Committee meeting materials. 2026.
8. US Food and Drug Administration. GenoGenix LLC warning letter. 2026.
9. Centers for Disease Control and Prevention. Signs and symptoms of stroke. 2026.
10. Centers for Disease Control and Prevention. Symptoms and danger signs of mild TBI and concussion. 2025.

Bottom line

Full-length thymosin beta-4 has produced neurological signals in rat TBI and stroke models, with mixed results across age and outcomes. The studies did not test TB-500, and neither compound has established human benefit or safety for neurological injury. The evidence supports further preclinical research—not self-treatment, a dosing protocol, or delaying emergency and specialist care.